JCPP advances · 2025
Systematic review: Safety and efficacy of atomoxetine in children and adolescents with autism spectrum disorder.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gupta Nihit, Boyes Daniel, Hanlon-Taylor Hunter, Gupta Mayank
Аннотация
BACKGROUND: This systematic review aimed to assess the current evidence on the efficacy and safety of Atomoxetine in common clinical attention-deficit hyperactivity disorder (ADHD) symptoms in the context of autism spectrum disorder (ASD) for children and adolescents. Some of these common clinical symptoms of ADHD in the context of ASD include core symptoms of ASD, ADHD, depression, anxiety, mood instability/irritability, and cognitive symptoms.
METHODS: Major medical literature were searched for randomized controlled trials (RCTs), open-label trials, and other relevant studies or clinical trials reporting on pediatric (age <18 years) patients with ASD treated with Atomoxetine for any reason. Databases were searched January of 2024 and include PubMed, Google Scholar, Web of Science, Scopus, PsycINFO, and Embase. Exclusion criteria were unpublished data and multiple reports from the same data set.
RESULTS: A total of 100 abstracts were screened, and 16 clinical trials were selected for inclusion. Out of these 16 clinical trials there were two RCTs (n = 128 and 97), four open-label trials (n = 24, 12, 12, and 16), eight extension studies (n = 128, 97, 88, 97, 97, 117, 128, and 94), one observational study (n = 4), and one crossover study (n = 16). Meta-analysis was not performed due to a lack of homogeneity in the two RCTs. There were limited studies available with a need for more high-power studies. In the current studies, most suggested that Atomoxetine was well tolerated and safe in pediatric patients with ASD. In fact, Atomoxetine response rates were found to be similar to those of methylphenidate in ASD studies, while inducing fewer adverse events and tolerated better.
CONCLUSION: Further trials are warranted to make conclusive recommendations on Atomoxetine for improvement of common clinical symptoms of ADHD in the ASD pediatric population. Given limited approved therapies for common clinical symptoms of ASD in children and adolescents, Atomoxetine could be used as a safe off-label option due to a favorable tolerability profile and minimal adverse effects.
METHODS: Major medical literature were searched for randomized controlled trials (RCTs), open-label trials, and other relevant studies or clinical trials reporting on pediatric (age <18 years) patients with ASD treated with Atomoxetine for any reason. Databases were searched January of 2024 and include PubMed, Google Scholar, Web of Science, Scopus, PsycINFO, and Embase. Exclusion criteria were unpublished data and multiple reports from the same data set.
RESULTS: A total of 100 abstracts were screened, and 16 clinical trials were selected for inclusion. Out of these 16 clinical trials there were two RCTs (n = 128 and 97), four open-label trials (n = 24, 12, 12, and 16), eight extension studies (n = 128, 97, 88, 97, 97, 117, 128, and 94), one observational study (n = 4), and one crossover study (n = 16). Meta-analysis was not performed due to a lack of homogeneity in the two RCTs. There were limited studies available with a need for more high-power studies. In the current studies, most suggested that Atomoxetine was well tolerated and safe in pediatric patients with ASD. In fact, Atomoxetine response rates were found to be similar to those of methylphenidate in ASD studies, while inducing fewer adverse events and tolerated better.
CONCLUSION: Further trials are warranted to make conclusive recommendations on Atomoxetine for improvement of common clinical symptoms of ADHD in the ASD pediatric population. Given limited approved therapies for common clinical symptoms of ASD in children and adolescents, Atomoxetine could be used as a safe off-label option due to a favorable tolerability profile and minimal adverse effects.